Antibody Screening Solutions Made Easy - 3

iologics continue to represent the fastest growing class of

iQue Screener PLUS's ability to perform multiple assays in every well

therapeutics in the biopharmaceutical industry. One of the key

to dial specificity and cross-reactivity criteria right into their primary

drivers behind this growth is the success in the clinic with anti-cancer

screens. Following primary screens with large scale, multiplexed assays

immunotherapy involving checkpoint modulation, chimeric antigen

to create comprehensive functional profiles on large numbers of

receptor T-cell therapy and bispecific T-cell engagers. While these

candidates further increases the chance of taking successful candidates

approaches employ different functional tactics to attack tumors, they

into downstream studies.

all utilize monoclonal antibody-based binding molecules to target
specific antigens.

In this eBook, we would like to share some articles that provide useful
information for scientists developing novel biologics. Take a look at
the webinars and papers that follow and learn why leaders in antibody

campaigns require technologies that enable rapid identification

discovery have made the Intellicyt iQue Screener PLUS platform an

and characterization of candidate molecules with superior target

integral part of their workflow.

reactivity and optimized functionality.
The Intellicyt® iQue Screener PLUS has become the discovery platform

Thomas Duensing,

of choice for screening monoclonal antibodies using libraries generated

Chief Technology Officer, Cell Analysis

from hybridomas, phage display and primary B-cells. Scientists use the

Intellicyt, Part of the Sartorius Group

media point inc / Getty Images

In this highly competitive field, successful antibody discovery
Antibody Screening Solutions Made Easy

Table of Contents for the Digital Edition of Antibody Screening Solutions Made Easy
